WESTSCHEME'S SUPPORT FOR RESEARCH AND INNOVATION

Westscheme is an industry superannuation fund based in WA, which strives to make money FOR its members - not FROM them.

Established in 1986, Westscheme has now grown to serve 204,446 members and 24,297 employers. These members have entrusted around $3 billion of their retirement savings to Westscheme.

While focussed on Western Australia, Westscheme draws its members from all over Australia. They work across a wide range of industries.

With members as young as 16, through to pensioners aged 55 and over, Westscheme attributes its success to its commitment to deliver safe, secure and profitable superannuation for life.

With the commencement of the Trans Tasman Commercialisation Fund, Westscheme members will have committed more than $215 million to the commercialisation of research and the nurturing of innovation since 2002. Westscheme believes in the excellence of Australasian research and ingenuity, and warmly welcomes the addition of an eminent New Zealand partner to this program. Westscheme’s support for this sector has been rewarded to date and it looks forward to continuing mutual benefit.

Westscheme members now support the commercialisation of research from Murdoch University in WA (the Murdoch Westscheme Enterprise Partnership – 2004, managed by Stone Ridge Ventures ); the University of Melbourne, the University of New South Wales and the University of Queensland through Uniseed  – 2005); and Auckland University in New Zealand, Monash University in Victoria, the University of Adelaide, Flinders University in South Australia and the University of South Australia (Trans Tasman Commercialisation Fund – 2008, managed by Brandon Capital ).  In addition in 2007 Westscheme committed to being a financial supporter of the Medical Research Commercialisation Fund in which a number of prominent Australian medical research institutes participate, based in Victoria, New South Wales and Western Australia.